

PE WAR N 6 2006 W

IE UNITED STATES PATENT AND TRADEMARK OFFICE

**Application Number** 

10/560,386

Confirmation No.:

TBA

First Named Inventor

INOUE et al.

I. A. Filing Date

: June 11, 2004

Title

: PYRIDINYLPYRAZOLOPYRIMIDINONE DERIVATIVES AS

PDE 7 INHIBITORS

TC/Art Unit

TBA

Examiner:

**TBA** 

Docket No.

: 58778.000005

Customer No.

: 21967

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

## MAIL STOP PCT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, and in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, Applicants are submitting herewith copies of the references other than U.S. patents and U.S. patent publications listed on the attached Form PTO/SB/08A (modified) for consideration and request the documents cited therein be made of record by the U.S. Patent and Trademark Office in the above-captioned application.

Several of the documents listed on the attached Form PTO/SB/08A (modified) were cited in the International Preliminary Report on Patentability, mailed on December 29, 2005, for International Application No. PCT/JP2004/008643 ("the International Preliminary Report"). Applicants note that these documents were previously submitted in Applicants' Information Disclosure Statement, filed on December 13, 2005. A copy of the International Preliminary Report is enclosed herein.

Consideration of the foregoing plus the prompt return of a copy of the enclosed Form PTO/SB/08A with the Examiner's initials in the left column in accordance with M.P.E.P. § 609 are respectfully requested.

ATTORNEY DOCKET: 58778.000005

Applicants respectfully point out that the submission of the listed documents in this Information Disclosure Statement is not an admission that they are prior art or that they are material to patentability of any claims of the application. Also, the submission of this Information Disclosure Statement is not an indication that a search has been made by Applicants.

For the convenience of the Examiner in considering the cited documents, a copy of each of the cited documents other than U.S. patents and U.S. patent publications is enclosed with this communication. In considering the cited documents, it may be noted by the Examiner that certain of the documents may contain markings, underlinings, and/or other notations. These markings, underlinings, and/or other notations are not to be construed as drawing the Examiner's attention either to selected parts or away from other parts of the cited documents. Any such markings were either present on the copies of the cited documents obtained by the associated individuals, or were made thereon during the study of the documents by the associated individuals.

In accordance with 37 C.F.R. § 1.97(b), this Information Disclosure Statement is believed to be submitted prior to issuance of a first Office Action. Therefore, it is respectfully submitted that no fee is required for consideration of this information. However, in the event any fee is deemed necessary, the Commissioner is authorized to charge the undersigned's Deposit Account No. 50-0206.

By:

Respectfully submitted,

**HUNTON & WILLIAMS LLP** 

Dated: March 6, 2006

Robert M. Schulman

Registration No. 31,196

Alexander H. Spiegler Registration No. 56,625

Hunton & Williams LLP Intellectual Property Department 1900 K Street, N.W. Suite 1200 Washington, DC 20006 (202) 955-1500 (telephone) (202) 778-2201 (facsimile) RMS/AHS:sac

PTO/SB/08B (08/03) (modified)

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

1 of 4

Sheet

## TANDEMARKS

MAR 0 6 2006

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number 10/560,386

I.A. Filing Date June 11, 2004

First Named Inventor INOUE et al.

Art Unit To be assigned

Examiner Name To be assigned

58778.000005

					OCUMENTS Pages, Columns, Li			
Examiner mitials	Cite No.		CUMENT NUMBER r - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Relevant Passages or Relevant Figures Appear		
		US	5,541,187	07-30-1996	Bacon et al.			
		,US	6,613,778	09-02-2003	Eggenweiler, et al.			
		US	6,627,651	09-30-2003	Shiraishi, et al.			
		US	6,737,436	05-18-2004	Eggenweiler, et al.			
		US	2004/0138279	07-15-2004	Eggenweiler, et al.			
 [		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
EXAM	INER S	IGNATURE	3		DATE CONSIDERED			

**Attorney Docket Number** 

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO						Application Number		10/560,386			
INFORMATION DICCLOCUDE					CTIBLE	I. A. Filing Date		June 11, 2004			
STATEMENT BY APPLICANT						Fi	rst Named Inventor	INOUE et al.			
						Ar	t Unit	To be assigned			
	(use as many sheets as necessary)						aminer Name	To be assigned			
Sheet		2 of	4			At	torney Docket Number	58778.000005			
				F	OREIGN F	AT	TENT DOCUMENTS	L			
	FOREIGN PATENT DOCUMENT										
*Examiner Initial	Cite No.			y Code Number-Kind Code (if known)	Publication D MM-DD-YYY		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION YES NO		
-			EP	1176147	01-30-200	2	Pfizer Limited, Pfizer Inc.				
			EP	1092720	04-18-200	1	Pfizer Limited, Pfizer Inc.				
			EP	0995750	04-26-200	0	Pfizer Limited, Pfizer Inc.				
			WO	01/34601	05-17-2001		Merck Patent GmbH				
-			WO	00/68203	11-16-200	0	Takeda Checmical Industries, LTD.				
			WO	01/32618	05-10-200	1	Merck Patent GmbH	·			
			DE	19950647	04-26-200	1	Merck Patent GmbH				
			WO	02/088080	11-07-200	2	Bristol-Myers Squibb Co.				
			WO	02/087513	11-07-200	2	Bristol-Myers Squibb Co.				
			WO	02/102315	12-27-200	2	Bristol-Myers Squibb Co.	A State of the April Condition of the April C			
			WO	02/074754	09-26-200	2	Warner-Lambert Co.				
			WO	02/028847	4-11-2002	2	Warner-Lambert Co.				
			WO	01/98274	12-27-200	1	Celltech Chiroscience Ltd.				
			WO	01/74786	10-11-200	1	Darwin Discovery LTD.	1,000			
			WO	02/40450	05-23-200	2	BYK Gulden Lomberg Chemische Fabrik GmbH				
			EP	463756	01-02-199	2	Pfizer, Inc.	100			
			EP	526004	02-03-199	3	Pfizer, Inc.				
			SIGNATU		ed, whether or	not	DATE CONSIDERED citation is in conformance wit	h MPEP 609. Draw line thro	ugh cits	ation if	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08B (08/03) (modified)

U.S. Patent	and Trademark	Office; U.S	S. DEPARTMENT	OF	COMMER	RCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT						Application Number  I. A. Filing Date  First Named Inventor		10/560,386  June 11, 2004  INOUE et al.			
					CHIDE						
(use as many sheets as necessary)						Art Unit		To be assigned			
		(use us	muny s	sneets as necessary)		Ex	aminer Name	To be assigned	· <del>-</del>		
Sheet		3 of 4				At	torney Docket Number	58778.000005			
FOREIGN P						'ΑΤ	TENT DOCUMENTS				
FOREIGN PATENT											
	DOCUMENT				Pages, Columns, Lines, Where	TRANSLATION					
* Examiner * oitial	Cite No.			y Code Number-Kind Code (if known)	Publication D		Name of Patentee or Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	YES	NO	
			EP	349239	01-03-199	0	Smith Kline & French Laboratories Ltd.				
			EP	636626	02-01-199	5	Laboratories Glaxo SA				
			EP	995751	04-26-200	0	Pfizer Limited, Pfizer Inc.				
			JP	08-253484	10-01-199	6	Taisho Pharmaceut. Co. Ltd.	Abstract			
		,									
				,							
				_							
					,,						
EX	EXAMINER SIGNATURE					DATE CONSIDERED					
*E	XAM I in co	INER:	Initial	if reference considere not considered. Incl	ed, whether or	not is fo	citation is in conformance wit	h MPEP 609. Draw line thro p applicant.	ugh cita	ition if	

PTO/SB/08B (08/03) (modified) U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

				Office, C.O. BEI ARTHUERT O				
Substitu	te for	form 1449/PTO	Application Number	10/560,386				
INE	'nΕ	RMATION DISCLOSURE	I. A. Filing Date	June 11, 2004				
		EMENT BY APPLICANT	First Named Inventor	INOUE et al.				
311		(use as many sheets as necessary)	Art Unit	To be assigned				
	,	use as many sneets as necessary).	Examiner Name	To be assigned	be assigned			
Sheet		4 of 4	Attorney Docket Number	58778.000005				
O.		OTHER DOCUMENTS - NON-	PATENT LITERATURE	DOCUMENTS				
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the						
nitials	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published					NO		
		Barnes et al. "Synthesis and Structure-Activity Relationships of Guanine Analogues as Phosphodiesterase 7 (PDE7) Inhibitors." Bioorg. Med. Chem. Lett. (2001), Vol. 11, pgs. 1081-1083.						
	Martinez et al. "Benzyl Derivatives of 2,1,3-Benzo- and Benzothieno[3,2-a]thiadiazine 2,2-Dioxides First Phosphodiesterase 7 Inhibitors." J. Med. Chem. (2000), Vol. 43, pgs. 683-689.							
	Castro et al. "CoMFA of benzyl derivatives of 2,1,3-benzo and benzothieno[3,2-a]thiadiazine 2,2 dioxides: clues for the design of phosphodiesterase 7 inhibitors." Eur. J. Med. Chem. (2001), Vol. 36 pgs. 333-338.							
		International Preliminary Report on Patentability for International Application No. PCT/JP2004/008643.						
					·			
_,								
<u>,</u>								
EXAMI	NER	SIGNATURE	DATE CONSIDERED					
		t: Initial if reference considered, whether or not coe and not considered. Include copy of this form v			itation i	f not		